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Abstract
People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life
expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is
attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and
dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other
metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening
and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European
Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving
the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare
professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and
treat cardiovascular risk factors and diabetes.
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People with severe mental illnesses (SMI), such as
schizophrenia, depression or bipolar disorder, have worse
physical health and reduced life expectancy compared to the
general population [58,82,84,124]. Evidence shows that they
have a 2–3 fold increased mortality rate and that the mortality* Corresponding author.
E-mail address: marc.de.hert@uc-kortenberg.be (M. De Hert).
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Open access under CC BY-NC-ND license.gap associated with mental illness compared to the general
population has widened in recent decades [113]. This excess
mortality is not only caused by increased suicide; people with
SMI have an increased risk of mortality associated with
physical illness, with the commonest cause of death being
cardiovascular disease (CVD) [15,16,17,25,26,65,82,103,104,
106,107]. The aetiology of this excess CVD is multifactorial
and includes genetic and lifestyle factors as well as disease
specific and treatment effects. People with SMI are more likely
to be overweight, to smoke and to have diabetes, hypertension
and dyslipidaemia [31,39,45,46,93,99,100,121]. They are more
Table 1
Estimated prevalence and relative risk of modifiable cardiovascular disease risk
factors in schizophrenia and bipolar disorder compared to the general popula-
tion [39,47].
Estimated prevalence and relative risk
Modifiable risk factors Schizophrenia Bipolar disorder
Obesity 45–55% RR: 1.5–2 21–49% RR: 1–2
Smoking 50–80% RR: 2–3 54–68% RR: 2–3
Diabetes 10–15% RR: 2 8–17% RR: 1.5–2
Hypertension 19–58% RR: 2–3 35–61% RR: 2–3
Dyslipidemia 25–69% RR:  5 23–38% RR:  3
Metabolic Syndrome 37–63% RR: 2–3 30–49% RR: 1.5–2
RR: relative risk.
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associated with chronic elevations of stress hormones.
Antipsychotic medication can induce weight gain or worsen
other metabolic CVD risk factors [5,51,61,64,99,100,116,117,
119,129,134,136]. There is emerging evidence that modifiable
cardiovascular risk factors are also increased in patients with
bipolar disorders and in those with a history of depression or
taking drugs to treat depression [8,12,13,15,16,25,27,38,67,
71,72,75,91,92,112,114,135]. The scientific literature regard-
ing the effects of medications used in the treatments of unipolar
or bipolar depression, such as antidepressants or mood
stabilisers, is currently less comprehensive than for antipsy-
chotics [11,12,15,91,92,141].
Despite the increased risk of diabetes and CVD risks, many
patients with SMI have limited access to general healthcare
with less opportunity for cardiovascular risk screening and
prevention than would be expected in a non-psychiatric
population [49,58,82,84,87]. Low rates of treatment for
hypertension, dyslipidaemia and diabetes have been reported
in schizophrenia patients [96]. The lack of consensus over who
should take responsibility for the general healthcare needs of
patients with mental illness has resulted in a continuing failure
to provide appropriate services.
Psychiatrists and primary care physicians should play an
active role in ensuring that patients with mental illness are not
disadvantaged. Measures should include the assessment and
management of cardiovascular risk factors and diabetes as part
of the care of their psychiatric patients. When indicated, shared
care with cardiologists, diabetologists, specialist nurses or other
specialists should be established.
The aim of the joint statement of European Psychiatric
Association (EPA), European Association for the Study of
Diabetes (EASD) and European Society of Cardiology (ESC) is
to reduce cardiovascular risk and to improve diabetes care in
patients with SMI and to improve the overall health and well-
being of the patients. This should reduce the burden of physical
illness for patients, their families and healthcare services.
Based on a review of the evidence that patients with SMI are
at increased risk of CVD and diabetes, this position statement
has been developed by the EPA, in consultation with the EASD
and the ESC. The statement is based upon the guidelines of ESC
and EASD [59].
2. Who is at risk and why?
2.1. Cardiovascular disease
Epidemiological studies have consistently shown excess
CVD mortality in patients with schizophrenia, bipolar disorder
and depression [8,15,17,18,24,26,35,82,83,106,107,113,124].
In a recent meta-analysis of 37 studies carried out in
25 countries, with an estimated total of nearly 23,000 deaths,
people with schizophrenia had a median all-cause standardised
mortality rate (SMR) of 2.58 (90% quantiles 1.18–5.76) (2.41
for all natural causes [90% quantiles 0.99–4.10], 7.5 for all
unnatural causes [90% quantiles 5.56–12.73]) [113]. The
median SMR for CVD was 1.79 (90% quantiles 1.11–3.60).The median all-cause SMR for people with schizophrenia
during the 1970s, 1980s and 1990s were 1.84, 2.98 and 3.20,
respectively, demonstrating increasing health inequalities with
an increasing mortality gap over time.
Similar findings have been reported in large studies of
people with affective disorders with an overall SMR ranging
from 1.23 to 2.50 [8]. In a subset of 400 patients with unipolar
depression or bipolar disorder followed up for 34–38 years, the
SMR for coronary heart disease (CHD) was 1.61 (confidence
interval [CI] 1.31–3.54). Compared with healthy women,
women with depression were particularly at risk of CHD
mortality (SMR 1.7, CI 1.34–2.14), while men showed
increased cerebrovascular and vascular mortality (SMR 2.21,
CI 1.29–3.54). The Baltimore Maryland Epidemiological
Catchment Area Study, which was a 13 years follow-up study
of a representative US community sample assessed for common
psychiatric illness, reported a 4.5 fold increased odds ratios for
myocardial infarction in patients with depression [57,109].
The aetiology of this excess CVD is multifactorial and
includes genetic and lifestyle factors as well as disease specific
and treatment effects. The excess CVD mortality associated
with schizophrenia, unipolar and bipolar disorder is widely
attributed to the 1–5 fold relative risk of the modifiable CVD
risk factors, obesity, smoking, diabetes, hypertension and
dyslipidaemia, in this group of patients compared with the
general public (Table 1) [5,9,13–16,33,39,41,43,47,64,65,74,
88,94,99,100,116,117,119,121,129,133,135,136].
In the USA, 68% of 689 schizophrenia patients who took
part in the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) study were smokers compared to
35% of age matched controls, 13% had diabetes versus 3%
of controls and 27% versus 17% had hypertension [60]. Patients
with schizophrenia also had significantly lower HDL-choles-
terol (HDL-C) levels. Approximately one third of patients in
CATIE had a constellation of metabolic and cardiovascular risk
factors at baseline [93].
In a meta-analysis including 12 papers on hypertension and
11 on dyslipidaemia, there was a pooled risk ratio of 1.11 (0.91
to 1.35) of hypertension. Although total cholesterol was not
higher in people with SMI (standardized mean difference
0.10 [0.55 to 0.36]), some, but not all, studies reported
lower levels of HDL-C and raised triglyceride levels [104].
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mellitus type 2 has also been found in clinical populations with
affective disorders [12,15,27,38,67,75,88,91,94].
Despite the high prevalence of cardiovascular risk factors,
there is evidence of undertreatment of these modifiable risk
factors. In the CATIE study, 88% of patients with dyslipidaemia
were receiving no treatment while 62% of those with
hypertension and 38% of those with diabetes also received
no treatment [96]. The high prevalence of undertreatment of
cardiovascular risk factors was recently confirmed in a study of
2463 people with schizophrenia from 12 European countries
[45]. Overall, 10.9% of patients were being treated for
hypertension, 7.1% for a lipid disorder and 3.5% for type 2
diabetes. Biochemical evidence of hyperglycaemia and
dyslipidaemia, however, was found in 26 and 70% of patients
respectively and untreated hypertension was found in 39%.
An unhealthy lifestyle, including poor diet and sedentary
behaviour, is likely to contribute to the adverse risk profile of
people with SMI. Given the weight gain and other metabolic
abnormalities associated with some second-generation anti-
psychotic agents (SGA), however it has been difficult to
differentiate the contribution of psychiatric conditions and
treatment per se to increased CVD risk [5,99,100,116,
117,119,130].
A large, ongoing, prospective study has confirmed that many
patients with first episode schizophrenia already have sign-
ificant metabolic abnormalities at the time of their first episode
of illness [43]. Twenty-seven percent of patients had raised total
cholesterol at first episode, rising to 61% in patients with a long
duration of illness. In addition, patients with first episode
psychosis have been found to have altered body composition
with increased intra-abdominal fat deposition as opposed to
subcutaneous fat, which itself has emerged as a strong and
independent risk factor for the development of CVD
[77,108,126,127]. The latter findings underline the importance
of possible metabolic alteration before the influence of
psychopharmacological treatment and support the hypothesis
that metabolic abnormalities are an inherent part of schizo-
phrenic illness, with socioeconomic factors and possibly
underlying genetic or biological factors playing a role
[100,116,117,119,130].
Dysregulation of the hypothalamic-pituitary adrenal axis
(HPAA) [13,15,28,66] and immunological alterations, such as
altered cytokine expression, are often seen in depression and
psychosis [111]. These findings may be involved in the
pathogenesis of CVD and give some insight into the
mechanisms by which psychiatric disease itself might
contribute to the pathogenesis of increased cardiovascular risk.
In addition, there appears to be a direct effect of the
antipsychotic medication on the ongoing development of CVD
risk factors [97,116,117,130].
2.2. Diabetes
Several studies have shown that the prevalence of diabetes is
2–3 fold higher than people with schizophrenia compared with
the general population. Several cross-sectional studies haveindicated that the prevalence of diabetes among populations of
people with schizophrenia is around 10–15%, or two to three
times higher than in the background population [68].
Data from the Baltimore Maryland Epidemiological
Catchment Area Study reported increased odds ratios for type
2 diabetes (OR = 2.2) and myocardial infarction (OR = 4.5) in
depressed patients [50,57,109].
One large, ongoing, prospective study in Belgium has
confirmed that a significant number of patients with schizo-
phrenia already have diabetes at the time of their first episode of
illness [43], with the prevalence of diabetes increasing from 3%
in first episode and recent-onset patients (up to 2 years in
treatment) to 16.5% in patients with a duration of illness of
more then 20 years. In this study, the prevalence of diabetes in
the age-band 15–25 years was five times more common in
patients with schizophrenia compared to the general popula-
tion.
Although there are fewer data, the prevalence of diabetes is
also higher among people with bipolar illness. A systematic
review by McIntyre and colleagues of all English language
articles published between 1966–2004 found that the pre-
valence of diabetes in bipolar illness was up to three times
greater than in the general population [91].
The reason for the increased incidence and prevalence of
diabetes in people with schizophrenia and bipolar illness, like
CVD risk, is multifactorial and includes genetic and lifestyle
factors as well as disease and treatment specific effects. An
increase in traditional diabetic risk factors such as family
history of diabetes, obesity and physical inactivity probably
account for much of the increased risk. It seems likely that these
risk factors operate in a similar manner to the general
population as illustrated by one previous study that showed that
diabetes increased with age and the presence of a family history
of diabetes increased the rate of diabetes in people with
schizophrenia by three-fold [81]. No study, however, has
examined the attributable risk of traditional diabetes risk factors
in people receiving antipsychotic medication. The effects of
antipsychotic drugs are discussed in the next section.
The association between depression and diabetes is complex
and there is evidence that the association is bidirectional
[16,67,112]. People with established diabetes have higher rates
of depression than the general population, while depression has
become established as a risk factor for diabetes. There are
several mechanisms to explain this association from the
‘‘psychological stress’’ resulting from the diagnosis and
treatment of the physical illness, through the metabolic
derangement leading to mood disturbance to alterations in
cytokines and stress hormones.
3. Psychopharmacological treatment and
cardiovascular disease risk
Psychopharmacological treatment with antipsychotics,
antidepressants and mood stabilisers is an effective and
necessary component of the management of severe mental
disorders like schizophrenic and affective disorders. As it is
well established that people with SMI who do not take
Table 2
Risk factors that predict weight gain.
Clinical Demographic
Choice of antipsychotic Younger age
First episode psychosis Lower initial BMI
Non-rapid cycling Personal history of obesity
Psychotic features Family history of obesity
Non-white ethnic background
Tendency to overeat in time of stress
Cannabis use
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admission than those who are on regular medication [128], any
adverse metabolic effect needs to be placed within the context.
Although the relationship between antidepressants and mood
stabilisers and weight gain is well described, the scientific
literature on the association between antidepressants or mood
stabilisers and cardiovascular risk is sparse. There is, however,
a considerable literature about the adverse effects of
antipsychotics.
Growing evidence suggests that children and adolescents
who take antipsychotic medication are at higher risk of weight
gain and metabolic effects than adults who use the same drugs
[32,36,79,80,103].
3.1. Weight gain
Weight gain during acute and maintenance treatment of
schizophrenia and affective disorders is a well established side
effect of antipsychotics affecting between 15–72% of patients
[1,2,5,11,29,51,61,71,85,88,101,116,117,130]. Antidepressants
and mood stabilising drugs, such as lithium and valproate, may
also induce significant weight gain.
There is a marked difference in the risk of weight gain
between different antipsychotic drugs. A meta-analysis of
clinical trials showed that after 10 weeks of treatment, weight
gain was greatest with clozapine (4.45 kg) and olanzapine
(4.15 kg) while quetiapine and risperidone (2.1 kg) had an
intermediate risk and aripiprazole, amisulpride and ziprasidone
have little effect on weight (<1 kg). No agent, however, should
be considered as truly weight-neutral as the proportion of
individuals experiencing more than 7% weight gain is greater
with any atypical antipsychotic than placebo [29]. It should be
underlined that in the meta-analysis by Allison et al. [1], some
of the first-generation antipsychotics (FGA or neuroleptics) like
chlorpromazine also showed a comparably high risk of
inducing weight gain. This hierarchy for risk of weight gain
has been confirmed in the more recent CATIE, the European
EUFEST studies and a meta-analysis [41,60,73,85,86].
There is marked inter-individual variation in weight change
for each drug, which may range from dramatic weight gain to
weight loss. Although weight gain is unpredictable for an
individual, there are several demographic and clinical features
that are associated with a greater propensity for weight gain and
should aid clinical decision-making (Table 2). In particular,
children and adolescents are at high risk of significant weight
gain. Early weight gain (> 7% body weight within the first
6 weeks of olanzapine treatment) appears to be a good predictor
of subsequent significant weight gain [76]. A comprehensive
literature review, however, did not find evidence for a dose–
response at the doses used to treated psychotic illnesses for
most antipsychotics, except clozapine and olanzapine [118].
Among the antidepressants, tricyclic agents (most notably
amitriptyline and doxepine), mitrazepine and paroxetine seem
to be associated with a higher risk of weight gain [91,92,123].
The mechanisms leading to antipsychotic-induced weight
gain are complex and are not fully understood. The main
mechanism of weight gain appears to be through appetitestimulation but other less specific mechanisms, such as altered
energy expenditure, may also be involved. Antipsychotics
interact with many different brain receptors involved with
appetite regulation, the most important of which are the
histamine H1 receptor, 5-HT2c receptor and b3 and a1
adrenergic receptors [5,71,96,99,100,116,117,130].
3.2. Dyslipidaemia
Prospective studies show that the use of antipsychotics is
associated with an increase in LDL cholesterol and decrease in
HDL-C [41,60,69,70,93]. Furthermore some comparative
studies have indicated that the effect on total and LDL
cholesterol differs between antipsychotics. At present, it is
uncertain whether these short-term changes will translate into
clinically relevant differences in the long term [41,60,73,93,
122,134,139].
The overall effect on triglycerides is more marked and here
there are clear differences between drugs; those drugs
associated with the most weight gain, such as clozapine and
olanzapine, are associated with the largest rise in serum
triglycerides [41,60,73,93,122,134,139]. The most marked
differences between drugs are seen in the early phase of
treatment when weight gain occurs most rapidly. In a recent
study on different cardiovascular risk factors in patients
diagnosed with schizophrenia from 2000–2006 compared to
1984–1995, those treated with SGA for 3 years gained twice as
much weight and showed greater deterioration in triglyceride
than those treated with FGA drugs for three years [46].
Most studies report lipid measurements after short periods of
treatment (2–3 months) and there is a need to assess what the
longer-term effects on triglyceride concentrations are once
weight has stabilised.
3.3. Hypertension
The literature does not show a consistent association
between SMI and hypertension. Antipsychotic drugs may
worsen hypertension through weight gain but this may be offset
by a hypotensive effect through adrenergic blockade.
3.4. Diabetes
An evaluation of the data regarding antipsychotic drugs is
challenging because of the increased risk of diabetes among
people with SMI. It is also complicated by the frequent changes
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long natural history of diabetes. The sources of information
range from case histories, through pharmaco-epidemiological
studies to randomised controlled studies. Many of these studies
have significant flaws and so it is not possible to draw firm
conclusions about the risks of diabetes with antipsychotic
medication [70].
Observational studies would suggest that there is an
increased risk of diabetes in people receiving an antipsychotic
medication. These studies, however, may be confounded by the
increased risk of diabetes in people with SMI. A recent meta-
analysis of the risk of diabetes in people with schizophrenia
receiving antipsychotics showed that there was a 1.32 (95% CI
1.15–1.51) fold increased risk of diabetes in people taking SGA
compared with conventional antipsychotics [119]. In this study,
no difference was found in the risk of diabetes between
different SGA. In a further systematic review of observational
cohort studies, the attributable risk for individual SGA relative
to FGA ranged from 53 more to 46 fewer new cases of diabetes
per 1000 patients with little observable difference between the
individual SGA versus FGA [30]. Furthermore, a systematic
review of the 22 prospective randomised controlled trials found
no consistent significant glucose abnormalities between any
comparator antipsychotics or placebo in any trial [21].
Although these studies would suggest that the risk of
diabetes associated with SGA medication is low, several
caveats are needed. There are clearly some cases of diabetes
and diabetic ketoacidosis that have occurred following
treatment with antipsychotic medication, including somewhere
this has occurred following re-challenge with the antipsychotic.
Diabetes may also remit following the discontinuation of
treatment.
Furthermore in several randomised controlled trials (RCT),
differences in blood glucose have been observed. For example,
in the CATIE study, there was a significantly greater increase in
HbA1c with olanzapine (0.4%) compared with quetiapine
(0.04%), risperidone (0.07%), perphenazine (0.09%) and
ziprasidone (0.11%). If these changes persisted with longer
treatment, they may translate into clinically meaningful
differences in the rates of diabetes between drugs [86].
The mechanism by which antipsychotic drugs induce
diabetes is not clear and again is likely to involve several
different systems. As well as an indirect effect on the risk of
diabetes through weight gain, in vitro and animal studies have
demonstrated that antipsychotics may have an effect on insulin
secretion and insulin resistance [99,105,116,117,130].
Overall, the evidence is clear that the use of antipsychotics is
associated with an increased risk of diabetes but this risk is
small compared with other traditional diabetic risk factors. The
evidence for a differential effect between different antipsycho-
tics is less conclusive. Given our understanding in the
relationship between obesity and diabetes, it is likely that that
where there is significant antipsychotic induced weight gain
leading to obesity over a prolonged period of treatment, this
may contribute to the development of diabetes. As such there
may be differences between antipsychotics in their risk for
diabetes.3.5. Cardiovascular events
A large UK study involving 46,136 people with SMI and
300,426 healthy controls demonstrated that the hazard ratios
(HR) for CHD mortality in people with SMI compared with
controls were 3.22 (95% CI, 1.99–5.21) for people 18 through
49 years old, 1.86 (95% CI, 1.63–2.12) for those 50 through
75 years old and 1.05 (95% CI, 0.92–1.19) for those older than
75 years. For stroke deaths, the HR were 2.53 (95% CI, 0.99–
6.47) for those younger than 50 years, 1.89 (95% CI, 1.50–2.38)
for those 50 through 75 years old and 1.34 (95% CI, 1.17–1.54)
for those older than 75 years. Compared with healthy controls,
people with SMI who were not prescribed any antipsychotics
were at increased risk of CHD and stroke than controls, whereas
those prescribed such agents were at even greater risk. Those
receiving the higher doses were at greatest risk of death from
both CHD and stroke. Exposure to atypical antipsychotics,
however, was not related to CHD mortality. Compared with the
non-SMI control group, the fully adjusted HR for CHD death in
the SMI subgroups were as follows: 1.38 (95% CI, 1.08–1.76)
for those not prescribed any antipsychotics, 0.86 (95% CI,
0.52–1.41) for those ever prescribed atypical antipsychotics and
2.12 (95% CI, 1.82–2.47) for those receiving conventional
antipsychotics only [104].
A well conducted retrospective pharmaco-epidemiological
cohort study involving over 90,000 people receiving anti-
psychotics found a 1.99–2.26 fold increased rate of sudden
cardiac death in current users of typical and atypical
antipsychotics [110]. The risk increased with higher doses
and was not seen in former users of antipsychotics. There was
no difference between typical and atypical antipsychotics. The
underlying reason for this finding was not fully established in
this study.
At the present time, there are no outcome data for the
differences in weight gain and risk of diabetes and
dyslipidaemia with each of the SGA’s in terms of hard
endpoints, such as non-fatal and fatal CVD and total mortality.
4. Guidelines for screening and monitoring of
cardiovascular disease risk factors and diabetes
Over recent years, both national and international groups
have developed screening and monitoring guidelines [5,10,22,
31,34,42,48,90,115,133,137] but these are not being routinely
implemented in the clinical care of patients [20,63,87,99],
although they appear to be cost-effective [19]. The most recent
NICE schizophrenia guidelines include the need for compre-
hensive physical health monitoring and involvement of general
practitioners [102]. Some recent diabetes guidelines have
defined a diagnosis of schizophrenia and antipsychotic use as
risk factors for diabetes [4,23].
5. Assessment of cardiovascular disease risk
The European Guidelines on CVD prevention recommend
that people with known CVD, type 2 diabetes or type 1 diabetes
with microalbuminuria or with very high levels of individual
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actively managed [59].
For other people, the Guidelines recommend that risk factors
should be managed according to the total CVD risk, as assessed
by the Score risk charts which calculate risk according to age,
sex, smoking habit, systolic blood pressure and total
cholesterol, or the ratio of total to HDL-C [59]. These charts
focus risk management on men over 50 and women over 55.
Recent evidence suggests that patients with SMI are
typically younger, have higher blood pressure and are more
likely to be smokers than the populations used to derive CVD
risk scoring systems, such as Framingham and Score and there
is a need to validate a risk score for this specific population of
mentally ill patients [9,19,37,41,60,125].
To ensure that younger patients at high CVD risk compared
to others the same age do not miss out on treatment, the
European Guidelines on CVD prevention include a relative risk
chart which bases the relative risk on smoking habit, systolic
blood pressure and total cholesterol (Fig. 1).
In the current absence of a risk scoring system for people
with SMI [125] and given the excess CVD mortality in people
with SMI outlined earlier, we recommend that the decision to
manage CVD risk factors in this group of patients should be
based on relative risk, as shown in Fig. 1. Where individual risk
factors are markedly raised, there may also be a need to manage
these on an individual basis.
As obesity and metabolic abnormalities are also seen in
children and adolescents who take antipsychotic medication are
at particularly high risk [32,36,79,80,103], we recommend
close monitoring of risk factors such as weight and lipid levels
in this group, with appropriate dietary, lifestyle and therapeutic
intervention, in line with recent paediatric guidance [40].
5.1. Which tests and when?
CVD risk assessment in the general population is usually
carried out within a primary care setting. Many patients with
serious mental health problems, however, frequently have poorFig. 1. Relative risk of fatal cardiovascular disease [59].access to general healthcare services. Such annual screening for
CVD and metabolic disorders in patients with SMI, however,
can be cost effective, owing to the reduction in costs of treating
the complications of diabetes [19,59].
Psychiatrists are often best placed to coordinate CVD risk
assessment and management, ideally as part of shared care
arrangements with general and specialist healthcare services.
It is particularly important to establish baseline CVD risk at
initial presentation so that any subsequent change during
treatment can be monitored.
The medical history and examination should therefore
include:
 history of previous CVD, diabetes or other related disease;
 family history of premature CVD, diabetes or other related
disease;
 smoking habit;
 weight and height in order to calculate body mass index
(BMI) and waist circumference;
 fasting blood glucose;
 fasting blood lipids: total cholesterol, triglycerides, LDL-
cholesterol (by calculation) and HDL-C;
 blood pressure (measured twice and average taken), heart
rate, heart and lung auscultation, foot pulses;
 ECG.
Normal and abnormal values for fasting blood glucose,
fasting blood lipids and blood pressure are provided in Table 3.
It is recommended that measurements should be taken at the
initial presentation and before the first prescription of
antipsychotic medication (Fig. 2). The frequency of testing
will depend on the patient’s medical history and the prevalence
of baseline risk factors.
For patients with normal baseline tests, it is recommended
that biochemical measurements are repeated at 6 weeks and
12 weeks after initiation of treatment and at least annually
thereafter. The frequency of testing will depend on the presence
of risk factors and detected abnormalities. During the initial
phase of treatment, it is important to measure weight weekly to
identify those individuals who gain weight rapidly with
psychotropic treatment.
In patients with diabetes, an assessment of glycaemia control
by HbA1c should be made regularly (approximately every
3 months) [6].
6. Management of cardiovascular disease risk factors
The recommended interventions for management of CVD
risk factors are summarised in Fig. 2.
6.1. Smoking habit
Smokers should be encouraged to stop smoking all forms of
tobacco. Those who demonstrate a readiness to quit can be
referred to a smoking cessation service which can offer
behavioural counselling, nicotine replacement therapy or other
pharmacological intervention.
Table 3
Abnormal values for major measurable cardiovascular disease risk factors
[59,138].
Abnormal value
Fasting blood glucose Impaired fasting glucose: between 6.1 and 7 mmol/l
(110–125 mg/dl)
Diabetes:  7.0 mmol/l (126 mg/dl)
Lipids
Total cholesterol Without diabetes: > 5 mmol/l (190 mg/dl)
With diabetes: > 4.5 mmol/l (175 mg/dl)
LDL-cholesterol Without diabetes: > 3 mmol/l (115 mg/dl)
With diabetes: > 2.5 mmol/l (100 mg/dl)
Blood pressure Without diabetes: > 140/90 mmHg
With diabetes: > 130/80 mmHg
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and healthcare staff from smoking on psychiatric wards and at
clinics is a useful first step towards smoking cessation
[56,120,132].
6.2. Body weight
Maintaining a healthy body weight and shape by healthy
eating and regular physical activity is the a key component of
lowering CVD risk and prompt action is needed in patients who
are overweight at initial assessment or who show signs of early
weight gain with antipsychotic medication.
Patients should be advised to lose weight if they have:
 BMI > 25 kg/m2 (especially if it is greater than 30 kg/m2);
 waist circumference greater than 88 cm in women or greater
than 102 cm in men.
A recent meta-analysis of 10 randomised trials involving
482 patients receiving antipsychotics was undertaken to assess
the effectiveness of lifestyle modification. The trials, which
lasted for 2–6 months and included studies that described the
prevention of treatment emergent weight gain as well as the
treatment of established obesity, found a statistically significant
reduction in mean body weight of around 2.5 kg with lifestyle
modification compared with usual treatment [3].
Referral to a nutritionist/dietician/personal trainer or life-
style programme should be considered [53,54–56]. Lifestyle
advice/support should include information about the impor-
tance of healthy eating and regular exercise [59]. Patients
should be advised to take 30 minutes of moderately vigorous
activity — at least a brisk walk — on most days of the week
Lifestyle advice/support must include information about the
importance of healthy eating and regular exercise [59]. Patients
should be advised to take 30 minutes of moderately vigorous
activity — at least a brisk walk — on most days of the week.
Referral to a nutritionist/dietician/personal trainer or lifestyle
programme could be considered.
Consideration should be given to switching antipsychotic
when an individual gains significant amount of weight,
particularly when the therapeutic response has been limited.Several pharmacological agents have been tried to reverse or
prevent antipsychotic-induced weight gain. No drug has been
found to be particularly effective but a recent systematic review
showed that there was preliminary evidence that metformin
may attenuate weight gain in both adult and adolescent patients
taking atypical antipsychotics [95,140]. While larger trials of
longer duration are needed, metformin may be considered in
patients with additional risk factors, such as a personal or
family history of metabolic dysfunction.
6.3. Diabetes and fasting blood glucose
The World Health Organisation (WHO) defined diabetes as a
fasting plasma glucose of 7 mmol/L or more (126 mg/dL)
[7,23,52,138]. In an asymptomatic individual, the diagnosis
should be confirmed with a second fasting measurement on
another day. The measurement of HbA1c may be used in the
future for diagnosing diabetes [129].
In all forms of diabetes, inadequate control of glycaemia will
result in complications of diabetes. These complications
include diabetic neuropathy, diabetic retinopathy, diabetic
kidney disease and an increased risk of infection. The goal of
metabolic control should be to achieve HbA1c levels below 7%
of total haemoglobin.
Patients with type 2 diabetes are likely to require additional
pharmacological management, but this should be no different
from the general population, for which guidelines are available
from the EASD and the American Diabetes Association (ADA)
[6].
Psychiatric centres should cooperate with diabetes centres to
establish shared care of patients with mental illness and
diabetes. For patients who require insulin treatment a diabetes
nurse educator from a diabetes centre should be available upon
request for patients in psychiatry units.
Patients with diagnosed diabetes should be seen by a
physician and/or a diabetes nurse regularly and as required
depending on the therapy used. Fasting blood glucose and
HbA1c should be measured regularly (approximately every 3–
6 months). An annual examination should include measurement
of CVD risk factors, urinary albumin excretion and serum
creatinine, an eye examination, ideally including fundus
photography, and foot examination to diagnose early signs
of complications [6].
Insulin treatment should be initiated and monitored by
healthcare professionals with expertise in the management of
diabetes. Special attention should be given to the prevention of
hypoglycaemia in patients on insulin treatment. Avoidance of
hypoglycaemia is best achieved by involving the patient’s
family and cares in the education process about the risks and
consequences of hypoglycaemia. Education of the patients on
insulin should include blood glucose monitoring and the
adaptation of the insulin doses based upon the values.
Patients with impaired fasting glucose, defined by the WHO
as fasting glucose between 6.1 and 7 mmol/l (110–125 mg/dl),
have high risk of diabetes and increased risk of CVD and so
particular care is needed to ensure that these individuals
undergo annual monitoring of glucose level and CVD risk
Fig. 2. Cardiovascular risk management in people with severe mental illness.
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in people, with SMI closer monitoring should be considered.
There have been several studies that have shown that
lifestyle intervention is effective in the prevention of type 2diabetes [78,131]. These programmes have involved dietary
modification, weight loss and increased physical activity. The
principles of these programmes are similar to those used in the
lifestyle modification programmes in people with SMI
M. De Hert et al. / European Psychiatry 24 (2009) 412–424420described above. Consequently, these programmes are expected
to have benefits, in terms of diabetes prevention although this
has not been formally tested in people with SMI.
The Diabetes Prevention Program also demonstrated that
metformin is associated with a reduction in incident diabetes.
For diabetes prevention, a Consensus Development Panel
recommended metformin use only for very-high-risk indivi-
duals (those with combined impaired fasting glucose and
impaired glucose tolerance, who are obese and under 60 years
of age with at least one other risk factor for diabetes). In
addition, the panel highlighted that in the Diabetes Prevention
Program, metformin was most effective compared to lifestyle in
those with BMI of at least 35 kg/m2 and those under age
60 years [98].
There is preliminary evidence that metformin improves
insulin sensitivity, glucose and HbA1c in people with SMI
[95,140]. In the absence of long-term studies of combined
antipsychotic and metformin therapy, consideration may be
given to the use of metformin in high-risk patients.
6.4. Fasting blood lipids
Management of elevated fasting lipid levels should be
carried out in the context of total CVD risk assessment (Fig. 1).
Target levels of total cholesterol and LDL-cholesterol are
less than 5 mmol/l (190 mg/dL) and less than 3 mmol/l
(115 mg/dL) respectively. More rigorous goals of less than
4.5 mmol/L (175 mg/dL) and less than 2.5 mmol/L (100 mg/
dL) are recommended for patients with established CVD or
diabetes (Table 3).
Patients should be encouraged to eat lean meat, fish and low
fat dairy products and to replace saturated fat with
monounsaturated and polyunsaturated fats from vegetable
and marine sources [59]. Those with mildly elevated
cholesterol levels may be able to reach target levels through
diet alone, while others are likely to require lipid lowering
therapy, usually with statins.
Statin treatment has been demonstrated to be effective in the
management of dyslipidaemia in patients with SMI [44,62].
Psychiatrists who are involved in ongoing lipid management
should be aware of the need for liver function and creatinine
kinase tests.
If total CVD risk is high (Score  5% over 10 years for fatal
CVD) then total cholesterol should be reduced to less than
5.0 mmol/l or less than 4.5 mmol/l in those with established
CVD or diabetes.
6.5. Blood pressure
High blood pressure in severely mentally ill patients is often
missed. Target blood pressure levels of less than 140/90 mmHg
are recommended.
Lifestyle changes, such as stopping smoking, reducing salt
intake, weight reduction and increased exercise, may be
sufficient to reduce mildly elevated blood pressure, although
some patients are likely to require pharmacological therapy.
Recently updated European guidelines stress the importance ofchoosing antihypertensive agents best suited to individual
patient’s needs [59,89].
6.6. Management of adverse drug-related effects on
cardiovascular disease risk factors
Choice of psychotropic medication should take account of
potential effects of different agents on CVD risk factors, such as
weight and glucose levels and lipid profiles, especially in
patients who are overweight or have diabetes or are at high total
CVD risk factors. Clinical decision-making is always complex
and has to consider efficacy aspects as well. A dilemma may
arise with clozapine which is recommended by many guidelines
as the antipsychotic of choice for those with refractory
schizophrenia as clozapine is associated with the highest risk of
weight gain and related CVD risk factors.
7. Summary and conclusion
The EPA, supported by the EASD and the ESC, published
this statement with the aim of improving the care of patients
suffering from SMI. The intention is to initiate cooperation and
shared care between the different healthcare professionals and
to increase the awareness amongst psychiatrists and primary
care physicians caring for patients with SMI of the need to
screen and treat increased cardiovascular risk factors and
diabetes.
In addition, the academic associations involved with this
statement point out that more research is required concerning
the cardiovascular problems of people with SMI and their
treatment.
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